<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6762">
  <stage>Registered</stage>
  <submitdate>28/03/2017</submitdate>
  <approvaldate>28/03/2017</approvaldate>
  <nctid>NCT03098550</nctid>
  <trial_identification>
    <studytitle>A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread</studytitle>
    <scientifictitle>Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2017-000367-33</secondaryid>
    <secondaryid>CA209-9GW</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Nivolumab
Other interventions - Daratumumab

Experimental: Immunotherapy Combination - 


Other interventions: Nivolumab
Specified dose on specified days

Other interventions: Daratumumab
Specified dose on specified days

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of adverse events (AE) - To establish the tolerability</outcome>
      <timepoint>Up to 2.5 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of serious adverse events (SAE) - To establish the tolerability</outcome>
      <timepoint>Up to 2.5 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Grade of laboratory abnormalities. - To establish the tolerability</outcome>
      <timepoint>Up to 2.5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response rate (ORR) - To evaluate ORR of nivolumab combined with daratumumab in participants with advanced or metastatic tumors in each cohort</outcome>
      <timepoint>Up to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS) - To assess PFS of nivolumab combined with daratumumab in participants with advanced or metastatic tumors in each cohort</outcome>
      <timepoint>Up to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-Drug Antibodies (ADA) positivity - To characterize the immunogenicity of nivolumab and daratumumab in participants with advanced or metastatic tumors</outcome>
      <timepoint>Up to 2.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve (AUC) - To characterize the pharmacokinetics of nivolumab and daratumumab in participants with advanced or metastatic tumors</outcome>
      <timepoint>Up to 2.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Minimum observed concentration (Cmin) - To characterize the pharmacokinetics of nivolumab and daratumumab in participants with advanced or metastatic tumors</outcome>
      <timepoint>Up to 2.5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

          -  Patients with metastatic or advanced solid tumors

          -  Women with histologically or cytologically confirmed triple negative breast carcinoma

          -  Participants with histologically or cytologically confirmed pancreatic adenocarcinoma

          -  Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer
             (NSCLC)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Active brain metastases or leptomeningeal metastases.

          -  Any serious or uncontrolled medical disorder

          -  Prior malignancy active within the previous 3 years

        Other protocol defined inclusion/exclusion criteria could apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>7/06/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>23/10/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Local Institution - St Leonards</hospital>
    <postcode>2065 - St Leonards</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex 08</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Majadahonda - Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Janssen Biotech, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab
      is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast
      Cancers, that have advanced or have spread.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03098550</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</name>
      <address />
      <phone>please email:</phone>
      <fax />
      <email>Clinical.Trials@bms.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>